| Autor: |
Sprenger-Svačina, Alina, Svačina, Martin K.R., Gao, Tong, Zhang, Gang, Sheikh, Kazim A. |
| Zdroj: |
Expert Opinion on Investigational Drugs; September 2024, Vol. 33 Issue: 9 p881-886, 6p |
| Abstrakt: |
ABSTRACTIntroductionGuillain-Barré syndrome (GBS) is a monophasic immune neuropathic disorder characterized by acute paralysis. A significant portion of patients are left with residual deficits, which presents a considerable global healthcare challenge. The precise mechanisms underlying GBS pathogenesis are not fully elucidated. Recent studies have focused on postinfectious molecular mimicry and identified involvement of IgG autoantibodies and innate immune effectors in GBS. Intravenous immunoglobulins (IVIg) and plasma exchange (PE) are two established evidence-based immunomodulatory treatments for GBS, but a significant proportion of GBS patients fails to respond adequately to either therapy. This emphasizes an urgent need for novel and more potent treatments.Areas coveredWe discuss novel immunomodulatory therapies presently at different phases of preclinical and clinical investigation. Some drugs in development target pathophysiologic mechanisms such as IgG autoantibody catabolism and complement activation, which are relevant to GBS.Expert opinionThere is an unmet need for more effective immune therapies for GBS. New immunomodulatory therapies under development may provide more potent options for GBS patients who do not respond to IVIg or PE. Future directions may include incorporating neuroprotective interventions based on evolving understanding of mechanisms underlying nerve injury and axonal degeneration. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
